JPIAMR is an international collaborative platform engaging 28 nations and the European Commission to curb antimicrobial resistance (AMR).
JPIAMR coordinates national public investments and funds for transnational research with the overarching goal to curb antimicrobial resistance (AMR) on a global scale. In a broad range of activities interlinked with the six priority areas of the shared JPIAMR Strategic Research and Innovations Agenda, SRIA, JPIAMR is seeking and supporting solutions to decrease the transmission of resistant bacteria. This is done in close collaboration with the 28 member countries and support from the European Commission. JPIAMR is one of the few global collaborative research funding platforms with a One Health approach.
Impact – investments in AMR research
JPIAMR coordinates jointly funded research project and network calls on a yearly basis in collaboration with member countries including deveolping aid agencies to support researchers in low- and middle-income countries. The UN, G7, G20 and the EU recognises JPIAMR as a key initiative to support and enable global collaboration and coordination of AMR research investments.
- To develop global AMR research strategies and programs through alignment of national and international research programs, by defining and implementing the JPIAMR Joint Strategic Research Agenda (SRA) and setting common (research) priorities
- To support and coordinate transformative research through open, national and joint transnational competitive calls for proposals
- To support and coordinate the JPIAMR Virtual Research Institute (JPIAMR-VRI)
- To promote innovation and translation of research results
- To bridge the gap between research and policy by collecting and sharing information on funded AMR research projects, research infrastructures, research output and impact with the scientific community and other relevant stakeholders.